Examining outcomes in STEMI patients with cardiogenic shock in Abu Dhabi
Official title: Clinical Characteristics and Outcomes Among ST-elevation Myocardial Infarction (STEMI) Patients With Cardiogenic Shock at Abu Dhabi City
Run by Abu Dhabi Health Services Company · NCT06535503 · Data updated 2026-11-12
This study looks at the health outcomes of patients in Abu Dhabi who had a serious heart attack complicated by shock to see how different treatments and patient factors affect their recovery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Abu Dhabi Health Services Company Government |
| Locations | 2 sites (Abu Dhabi, Abu Dhabi Emirate and 1 other locations) |
| Status | Recruiting |
| Started | July 1, 2024 |
| Main results expected | January 1, 2025 |
| Study ends | May 30, 2025 |
| Registry record updated | February 17, 2025 |
| Trial ID | NCT06535503 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 who were hospitalized for STEMI complicated by cardiogenic shock at the participating hospitals.
✕Probably not a fit
Patients under 18 or those with cardiogenic shock not related to myocardial infarction will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study analyzes the clinical characteristics and treatment outcomes of patients who experienced ST-elevation Myocardial Infarction (STEMI) complicated by cardiogenic shock (CS) at two major hospitals in Abu Dhabi, UAE, from 2020 to 2024. By reviewing electronic medical records, the study aims to identify treatment trends, hospitalization events, and patient demographics that influence recovery or mortality rates. The research addresses the high mortality rates associated with cardiovascular disease in the UAE and seeks to fill gaps in existing knowledge regarding STEMI and CS in the region.
Why it matters
Potential benefit: If successful, this study could improve understanding of treatment outcomes for STEMI patients with cardiogenic shock, potentially leading to better management strategies.
How similar studies have gone: While there is limited research specifically on this population in the UAE, similar studies in other regions have shown success in identifying treatment outcomes for STEMI patients with cardiogenic shock.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age more than 18. * STEMI complicated by cardiogenic shock. * Were hospitalized or treated at SSMC or SKMC for STEMI complicated by cardiogenic shock. * Patient admitted between January 2019 to March 2024. Exclusion Criteria: * Age less than 18. * Shock patient not related to Myocardial infarction. * NSTEMI-related cardiogenic shock. * Patients who were not treated at SSMC or SKMC for the STEMI complicated by cardiogenic shock. * Patient not admitted between January 2019 to March 2024.
Where it's running
-
Sheikh Khalifa Medical City (SKMC)
Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates Recruiting -
Sheikh Shakhbout Medical City (SKMC)
Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates Recruiting
Study contacts
- Principal investigator: Babiker Babiker Mohamed Babiker Elsiraj MB Elsiraj — Sheikh Shakhbout Medical City
- Study coordinator: Alina Naeem, MBBS
- Email: alnaeem@seha.ae
- Phone: 0097124102534
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Factors Influencing Outcomes in ECMO and Impella Patients
This study tests whether metabolic and thyroid hormone changes help predict survival for adults on ECMO or Impella at a single Hungarian cardiac ICU.
-
Evaluating a noninvasive tissue sensor to detect cardiogenic shock earlier in heart patients
This pilot, noninvasive study tests whether the NIRSense wearable can help detect deterioration in adults with cardiogenic shock risk due to heart attack or heart failure.
-
Smartphone AI help for prehospital ECG readings
This study tests whether using a smartphone AI (GPT-4o) to help prehospital providers read 12-lead ECGs improves accuracy in diagnosing acute coronary syndromes and related conditions.
-
Safety and Efficacy of an Extracorporeal Ventricular Assist System for Cardiogenic Shock
This study tests whether an extracorporeal ventricular assist device can safely provide short-term heart support and help patients with cardiogenic shock or trouble weaning from bypass.
-
Left Ventricular Support and Advanced Monitoring in AMI–Cardiogenic Shock: Immediate Impella Use and PAC/Monitoring vs Standard Care
In adults with heart attack-related cardiogenic shock, this trial tests whether using an Impella left ventricular assist device and/or protocolized pulmonary artery catheter monitoring improves survival compared with standard care.
-
CRP Apheresis for infarct-related cardiogenic shock
This study tests whether selectively removing C-reactive protein with apheresis, in addition to standard care, helps people with cardiogenic shock after a heart attack.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.